Adult Congenital Heart Disease International EValuation of the Effectiveness of SGLT2i Registry

ConditionsAdult Congenital Heart Disease Congenital Heart Disease Systemic Right Ventricle Transposition of the Great Arteries Congenitally Corrected Transposition of the Great Arteries Fontan Single Ventricle Tetralogy of Fallot (TOF)

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18+

SponsorLeiden University Medical Center

About this trial

This real-world, international registry aims to evaluate the current experience with sodium-glucose cotransporter 2 inhibitors (SGLT2i) in adult congenital heart disease (ACHD) patients by investigating the prescription patterns, safety, tolerability, and potential beneficial effects on heart failure-related outcomes.

Eligibility criteria

Qualifiers

Congenital heart defect.

Age ≥ 18 years.

Initiated on treatment with an SGLT2i.

Disqualifiers

None

Trial design

Treatments tested in this trial

SGLT2 inhibitors

Treatment groups

400 Participants

are divided into 1 treatment group

Locations

Germany

Heart Center Duisburg (Evangelical Hospital Niederrhein) Duisburg Germany

Netherlands

Leiden University Medical Center (LUMC)2333ZA, LeidenSouth Holland, Netherlands

Amsterdam University Medical Center Amsterdam Netherlands

University Medical Center Utrecht Utrecht Netherlands

Sponsors and collaborators

Leiden University Medical Center

Lead sponsor

Source ClinicalTrials.gov